

New Protocols Under development - As of September 30, 2026

Disease	Title/PI	Planned Activation
CTEP studies		
BN	NRG-BN015: Randomized phase 3 clinical trial of postoperative radiotherapy versus postoperative surveillance for clinical low-risk, molecular high-risk meningioma and longitudinal surveillance for clinical and molecular low-risk meningioma	Q4 2026
BN	NRG-BN016: Randomized Phase II Trial of Irradiation Alone Versus Irradiation Plus Abemaciclib in RB-Intact NRG High-Risk Meningioma (w/Safety lead-in)	Q1/Q2 2027
GI	NRG-GI013: Ablative Radiation Therapy To Liver Metastases For Immuno-Oncology (IO) Response in Microsatellite Stable (MSS) Colon Cancer (the RADIO study)	Q4 2026
GYN	NRG-GY038: A Phase II trial of sacituzumab govitecan (SG) and bevacizumab versus standard of care carboplatin, liposomal doxorubicin and bevacizumab in patients with platinum-sensitive ovarian cancer that has progressed on prior maintenance PARP inhibitor therapy	Activated September 4, 2026
GYN	NRG-GY039: A Phase III Non-Inferiority Trial of Hypofractionated Chemoradiation Therapy Versus Standard Chemoradiation for Cervical Cancer	Q1/Q2 2027
LU	NRG-LU011: A Phase II Randomized Study of Reirradiation for Locally Recurrent Non-Small Cell Lung Cancer	Q4 2026
LU	NRG-LU012: A Randomized Phase 3 Study of Dose-Painted SBRT: A Study for Ultracentral Early-Stage NSCLC	Q2/Q3 2027
LU	NRG-LU013: SORT: A Randomized Phase II Study of Sequencing Osimertinib, Radiation, and Chemotherapy in Stage III NSCLC with activating EGFR mutations.	Q2 2027
NCORP	NRG-CC016: Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)	Q3/Q4 2026
NCORP	NRG-CC018: Mi Sleep Coach App for Cancer-Related Insomnia	Q2 2027